WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124281
CAS#: N/A
Description: IACS-52825 is a Potent and Selective DLK Inhibitor(IC50 = 107 nM) for Treatment of Chemotherapy-Induced Peripheral Neuropathy. IACS-52825 showed strongly effective reversal of mechanical allodynia in a mouse model of CIPN.
Hodoodo Cat#: H124281
Name: IACS-52825
CAS#: N/A
Chemical Formula: C16H13F7N4O2
Exact Mass: 426.09
Molecular Weight: 426.290
Elemental Analysis: C, 45.08; H, 3.07; F, 31.20; N, 13.14; O, 7.51
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: IACS-52825; IACS52825; IACS 52825
IUPAC/Chemical Name: (R)-1-(4-(6-amino-5-(trifluoromethoxy)pyridin-3-yl)-1-(3-fluorobicyclo[1.1.1]pentan-1-yl)-1H-imidazol-2-yl)-2,2,2-trifluoroethan-1-ol
InChi Key: XUOJHVFYSAMHNK-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H13F7N4O2/c17-13-4-14(5-13,6-13)27-3-8(26-12(27)10(28)15(18,19)20)7-1-9(11(24)25-2-7)29-16(21,22)23/h1-3,10,28H,4-6H2,(H2,24,25)
SMILES Code: FC1(C2)CC2(N3C([C@@H](O)C(F)(F)F)=NC(C4=CN=C(N)C(OC(F)(F)F)=C4)=C3)C1
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 426.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
Le K, Soth MJ, Cross JB, Liu G, Ray WJ, Ma J, Goodwani SG, Acton PJ, Buggia-Prevot V, Akkermans O, Barker J, Conner ML, Jiang Y, Liu Z, McEwan P, Warner-Schmidt J, Xu A, Zebisch M, Heijnen CJ, Abrahams B, Jones P. Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy. J Med Chem. 2023 Jul 12. doi: 10.1021/acs.jmedchem.3c00788. Epub ahead of print. PMID: 37436942.